Belén Otero Carrasco

Ms. Belén Otero Carrasco

Universidad Politécnica de Madrid, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022
Verified
Conference Paper
Closed access
AMAdrian Ayuso Munoz
Adrian Ayuso Munoz
ECEsther Ugarte Carro
Esther Ugarte Carro
LSLucia Prieto Santamaria
Lucia Prieto Santamaria
Belén Otero CarrascoBelén Otero Carrasco
Belén Otero Carrasco
ERErnestina Menasalvas Ruiz
Ernestina Menasalvas Ruiz
ARAlejandro Rodriguez-Gonzalez
Alejandro Rodriguez-Gonzalez
In recent years and due to COVID-19 pandemic, drug repurposing or repositioning has been placed in the spotlight. Giving new therapeutic uses to already existing drugs, this discipline allows to streamline the drug discovery process, reducing the costs and risks inherent to de novo development. Computational approaches have gained momentum, and emerging techniques from the machine learning domain have proved themselves as highly exploitable means for repurposing prediction. Against this backdrop, one can find that biomedical data can be represented in terms of graphs, which allow depicting in a very expressive manner the underlying structure of the information. Combining these graph data structures with deep learning models enhances the prediction of new links, such as potential disease-drug connections. In this paper, we present a new model named REDIRECTION, which aims to predict new disease-drug links in the context of drug repurposing. It has been trained with a part of the DISNET biomedical graph, formed by diseases, symptoms, drugs, and their relationships. The reserved testing graph for the evaluation has yielded to an AUROC of 0.93 and an AUPRC of 0.90. We have performed a secondary validation of REDIRECTION using RepoDB data as the testing set, which has led to an AUROC of 0.87 and a AUPRC of 0.83. In the light of these results, we believe that REDIRECTION can be a meaningful and promising tool to generate drug repurposing hypotheses.

16 September 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
Belén Otero CarrascoBelén Otero Carrasco
Belén Otero Carrasco
Lucía Prieto SantamaríaLucía Prieto Santamaría
Lucía Prieto Santamaría
ECEsther Ugarte Carro
Esther Ugarte Carro
JCJuan Pedro Caraça-Valente
Juan Pedro Caraça-Valente
AGAlejandro Rodríguez González
Alejandro Rodríguez González
Rare diseases are a group of uncommon diseases in the world population. To date, about 7000 rare diseases have been documented. However, most of them do not have a known treatment. As a result of the relatively low demand for their treatments caused by their scarce prevalence, the pharmaceutical industry has not sufficiently encouraged the research to develop drugs to treat them. This work aims to analyse potential drug-repositioning strategies for this kind of disease. Drug repositioning seeks to find new uses for existing drugs. In this context, it seeks to discover if rare diseases could be treated with medicines previously indicated to heal other diseases. Our approaches tackle the problem by employing computational methods that calculate similarities between rare and non-rare diseases, considering biological features such as genes, proteins, and symptoms. Drug candidates for repositioning will be checked against clinical trials found in the scientific literature. In this study, 13 different rare diseases have been selected for which potential drugs could be repositioned. By verifying these drugs in the scientific literature, successful cases were found for 75% of the rare diseases studied. The genetic associations and phenotypical features of the rare diseases were examined. In addition, the verified drugs were classified according to the anatomical therapeutic chemical (ATC) code to highlight the types with a higher predisposition to be repositioned. These promising results open the door for further research in this field of study.

24 May 2022
Verified
Book Chapter
Closed access
PDF file
Belén Otero CarrascoBelén Otero Carrasco
Belén Otero Carrasco
Lucía Prieto SantamaríaLucía Prieto Santamaría
Lucía Prieto Santamaría
ECEsther Ugarte Carro
Esther Ugarte Carro
JCJuan Pedro Caraça-Valente
Juan Pedro Caraça-Valente
AGAlejandro Rodríguez González
Alejandro Rodríguez González

26 April 2024
Verified
Conference Paper
Open access
PDF file
Belén Otero CarrascoBelén Otero Carrasco
Belén Otero Carrasco
Lucía Prieto SantamaríaLucía Prieto Santamaría
Lucía Prieto Santamaría
AGAlejandro Rodríguez González
Alejandro Rodríguez González
Drug repurposing represents a pivotal strategy for the expeditious administration of efficacious treatments for specific diseases in a more time- and cost-efficient manner [1]. The majority of successful repurposing instances adhere to a conventional paradigm derived from novel drug development. This paradigm is rooted in the concept of “one-drug-one-target-one-disease”, wherein drugs are tailored for individual diseases and their corresponding gene targets. This research examines the potential of biological pathways as a complementary means of enhancing the success of drug repurposing initiatives [2]. The current study is based on data from the DISNET platform [3], which aims to enhance our understanding of diseases and facilitate the repurposing of drugs by integrating biomedical data on a large scale. A comprehensive analysis was conducted on successful cases of drug repurposing, focusing on instances where biological pathways serve as the foundational framework for success. These cases are defined as DREBIOP (Drug REpurposing based on BIOlogical Pathways). By identifying these pathway-based repurposing cases, we delved into their underlying patterns, analyzing the diverse biological elements and pathways involved. Our analysis put forward a distinct collection of drug repurposing cases, named DREBIOP as previously defined, which are characterized by the dominant role of biological pathways. Furthermore, we employed the Mann-Whitney U Test to compare gene-disease association values and illustrate the reduced significance of drug target genes in these cases. This was done by contrasting the values of gene-disease association scores in the DREBIOP set with overall association values found in DISNET, as well as with the drug target gene-based repurposing cases (which we name as DREGE (Drug REpurposing based on GEnes)). A significant difference was observed between these gene disease association scores of DREBIOP and DREGE cases (p-value < 0.05). After identifying cases in the DREBIOP set in which the repurposing process was a result of connections through biological pathways, and discovering the most relevant characteristics of these cases, a new drug repurposing approach was developed. This novel approach is based on the direct relationship that exists between different diseases through a biological pathway. Thus, if we have "Disease 1" - Pathway - "Disease 2", drugs used to treat Disease 2 could be considered as candidates to treat Disease 1, inferred by its association to the same pathway. To perform this method, direct disease-pathway associations were obtained from WikiPathways1. “As of 02/24/2023, a total of 725 different associations were obtained comprised of 325 different pathways identified by WikiPathways identifiers, and 355 different diseases identified by the Concept Unique Identifier from the Unified Medical Language System (from now on, UMLS CUIs).”. These were used to create "Disease 1" - Pathway - "Disease 2" triplets, where disease sharing pathways were related. Through this association, 2,000 different triplets were obtained. Drug candidates for Disease 2 were then determined to be either previously associated with Disease 1 or newly discovered using this method. By associating Disease 1 with all possible candidate treatments for Disease 2, a total of 21,968 records were obtained using the DISNET database to check whether the association was new or had already been previously described (known), 76.7% of the associations between Disease 1 and potential drugs were found to be new. Of the original 2,000 triplets, new cases were obtained for 821 of them. Thus, a very large number of new potential candidates for the treatment of these diseases have been identified through the current analysis. A review of the scientific literature was then conducted to examine specific examples of these associations to determine if these findings had been previously investigated in clinical trials or if there were studies supporting this relationship. This process paved the way to understand the potential of repurposing each of these drugs for the identified disease. One of the examples studied confirming the potential of this method was the association between Huntington's disease (with UMLS CUI C0020179) and Schizophrenia (with UMLS CUI C0036341) through the phosphodiesterase in neuronal function pathway (with WikiPathways Identifier WP4222). Of the Huntington's disease-related drugs, 7 are potential candidates for the treatment of schizophrenia due to their common pathway. One of these drugs is Tetrabenazine, a vesicular monoamine transporter 2 (VMAT) inhibitor used to treat chorea associated with Huntington's disease [4]. Several studies have investigated the efficacy of this drug in schizophrenia [5], [6]. A recent meta-analysis concluded that tetrabenazine was moderately or highly effective in about three quarters of patients with schizophrenia or psychosis who were treated with it [7]. In conclusion, biological pathways emerge as one potential element to be considered for some specific drug repurposing efforts. Our research reveals discernible patterns that distinguish cases of pathway-based repurposing from the classical paradigm. These findings provide not just insights into the importance of pathway-based repurposing but also provide a new approach to drug repurposing based on biological pathways.

7 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Belén Otero CarrascoBelén Otero Carrasco
Belén Otero Carrasco
PNPaloma Tejera Nevado
Paloma Tejera Nevado
RMRafael Artiñano Muñoz
Rafael Artiñano Muñoz
GFGema Díaz Ferreiro
Gema Díaz Ferreiro
APAurora Pérez Pérez
Aurora Pérez Pérez
AGAlejandro Rodríguez González
Alejandro Rodríguez González
Proteins are fundamental biomolecules composed of one or more chains of amino acids. They are essential for all living organisms, contributing to various biological functions and regulatory processes. Alterations in protein structures and functions are closely linked to diseases, emphasizing the need for in-depth study. A thorough understanding of these associations is crucial for developing targeted and more effective therapeutic strategies.Computational analyses of biomedical data facilitate the identification of specific patterns in proteins associated with diseases, providing novel insights into their biological roles. This study introduces a computational approach designed to detect relevant sequence patterns within proteins. These patterns, characterized by specific amino acid arrangements, can be critical for protein functionality. The proposed methodology was applied to proteins targeted by drugs used in lung cancer treatment, a disease that remains the leading cause of cancer-related mortality worldwide. Given that non-small cell lung cancer represents 85–90% of all lung cancer cases, it was selected as the primary focus of this study.Significant sequence patterns were identified, establishing connections between drug-target proteins and proteins associated with lung cancer. Based on these findings, a novel computational framework was developed to extend this pattern-based analysis to proteins linked to other diseases. By employing this approach, relationships between lung cancer drug-target proteins and proteins associated with four additional cancer types were uncovered. These associations, characterized by shared amino acid sequence features, suggest potential opportunities for drug repurposing. Furthermore, validation through an extensive literature review confirmed biological links between lung cancer drug-target proteins and proteins related to other malignancies, reinforcing the potential of this methodology for identifying new therapeutic applications.

1 July 2022
Verified
Conference Paper
Closed access
DGDaniel Gomez-Bravo
Daniel Gomez-Bravo
AGAaron Garcia
Aaron Garcia
GVGuillermo Vigueras
Guillermo Vigueras
BRBelen Rios-Sanchez
Belen Rios-Sanchez
Belén Otero CarrascoBelén Otero Carrasco
Belén Otero Carrasco
AGAlejandro Rodriguez Gonzalez
Alejandro Rodriguez Gonzalez
Lung cancer is the leading cause of cancer death. More than 236,740 new cases of lung cancer patients are expected in 2022, with an estimation of more than 130,180 deaths. Improving the survival rates or the patient's quality of life is partially covered by a common element: treatments. Cancer treatments are well known for the toxic outcomes and secondary effects on the patients. These toxicities cause different health problems that impact the patient's quality of life. Reducing toxicities without a decline on the positive survival effect is an important goal that aims to be pursued from the clinical perspective. On the other hand, clinical guidelines include general knowl-edge about cancer treatment recommendations to assist clinicians. Although they provide treatment recommendations based on cancer disease aspects and individual patient features, a statistical analysis taking into account treatment outcomes is not provided here. Therefore, the comparison between clinical guidelines with treatment patterns found in clinical data, would allow to validate the patterns found, as well as discovering alternative treatment patterns. In this work, we have analyzed a dataset containing lung cancer patients information including patients' data, prescribed treatments and outcomes obtained. Using a Subgroup Discovery method we identify patterns based on cancer stage while relying on treatment outcomes. Results are compared with clinical guide-lines and analyzed based on statistical and medical relevance using Subgroup Discovery metrics.